| Range: | 24.7-27.72 | Vol Avg: | 3685 | Last Div: | 2.97 | Changes: | 0 |
| Beta: | 0.17 | Cap: | 1.51B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Dec 29 2022 | Empoloyees: | 217 | ||
| CUSIP: | CIK: | ISIN: | US4158583074 | Country: | US | ||
| CEO: | Mark L. Baum | Website: | https://www.harrowinc.com | ||||
HROWM 26.35 Stock Price Harrow Health, Inc. 11.875% Senior Notes due 2027
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow